Standard BioTools Inc. (LAB)
Standard BioTools Inc. (LAB) Stock Price, Analysis & Data
| Bid | 0.55 |
| Market Cap | 308.02M |
| Revenue (ttm) | 84.6M |
| Net Income (ttm) | -53.93M |
| Beta | n/a |
| EPS (ttm) | -0.13 |
| PE Ratio (ttm) | n/a |
| Forward PE | -78.46 |
| P/B (ttm) | 0.57 |
| P/S (ttm) | 3.64 |
| Earnings Date | Nov 3, 2026 |
| Ask | 1 |
| Volume | 238,580 |
| Avg. Volume (20D) | 3,434,572 |
| Open | 0.77 |
| Previous Close | 0.79 |
| Day's Range | 0.77 - 0.79 |
| 52-Week Range | 0.70 - 1.72 |
| Analyst | Hold |
| Price Target | 1.35 (73.08%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LAB
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses....
Financial Performance
In 2025, Standard BioTools's revenue was 85.33M, a decrease of -6.24% compared to the previous year's 91.01M. Earnings were -74.9M, a decrease of -46.07%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for LAB stock is "Hold". The 12-month stock price forecast is 1.35, which is upside of 73.08% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
